USPH Deferred Long Term Liab from 2010 to 2024

USPH Stock  USD 98.76  1.68  1.73%   
US Physicalrapy's Deferred Long Term Liabilities is increasing with slightly volatile movements from year to year. Deferred Long Term Liabilities is predicted to flatten to about 1.4 M. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2011-06-30
Previous Quarter
21.5 M
Current Value
23.1 M
Quarterly Volatility
7.3 M
 
Yuan Drop
 
Covid
Check US Physicalrapy financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among US Physicalrapy's main balance sheet or income statement drivers, such as Interest Expense of 9.8 M, Total Revenue of 635 M or Gross Profit of 117.6 M, as well as many indicators such as Price To Sales Ratio of 2.99, Dividend Yield of 0.0194 or PTB Ratio of 4.71. USPH financial statements analysis is a perfect complement when working with US Physicalrapy Valuation or Volatility modules.
  
Check out the analysis of US Physicalrapy Correlation against competitors.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.

Latest US Physicalrapy's Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of US Physicalrapy over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. US Physicalrapy's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in US Physicalrapy's overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

USPH Deferred Long Term Liab Regression Statistics

Arithmetic Mean1,568,087
Geometric Mean0.00
Coefficient Of Variation45.01
Mean Deviation589,888
Median1,575,000
Standard Deviation705,757
Sample Variance498.1B
Range2.5M
R-Value0.72
Mean Square Error256.3B
R-Squared0.52
Significance0
Slope114,029
Total Sum of Squares7T

USPH Deferred Long Term Liab History

20241.4 M
20232.5 M
20182.2 M
20172.1 M
20161.6 M
20151.4 M
2014null

About US Physicalrapy Financial Statements

Investors use fundamental indicators, such as US Physicalrapy's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although US Physicalrapy's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Deferred Long Term Liabilities2.5 M1.4 M

Currently Active Assets on Macroaxis

When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:
Check out the analysis of US Physicalrapy Correlation against competitors.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.24)
Dividend Share
1.75
Earnings Share
0.88
Revenue Per Share
42.489
Quarterly Revenue Growth
0.12
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.